Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Income from Continuing Operations (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Income from Continuing Operations for 4 consecutive years, with 20828000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations fell 35.02% to 20828000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 75101000.0, a 31.13% decrease, with the full-year FY2024 number at 60945000.0, down 27.88% from a year prior.
  • Income from Continuing Operations was 20828000.0 for Q3 2025 at Orchestra BioMed Holdings, down from 19363000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 813415.0 in Q3 2022 to a low of 20828000.0 in Q3 2025.
  • A 4-year average of 12925694.33 and a median of 13407000.0 in 2024 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: plummeted 1573.07% in 2023, then dropped 13.35% in 2024.
  • Orchestra BioMed Holdings' Income from Continuing Operations stood at 9828000.0 in 2022, then dropped by 26.99% to 12481000.0 in 2023, then fell by 29.44% to 16155000.0 in 2024, then fell by 28.93% to 20828000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Income from Continuing Operations are 20828000.0 (Q3 2025), 19363000.0 (Q2 2025), and 18755000.0 (Q1 2025).